166 related articles for article (PubMed ID: 8523074)
1. Prognostic implications of chromosome 17p deletions in human medulloblastomas.
Batra SK; McLendon RE; Koo JS; Castelino-Prabhu S; Fuchs HE; Krischer JP; Friedman HS; Bigner DD; Bigner SH
J Neurooncol; 1995; 24(1):39-45. PubMed ID: 8523074
[TBL] [Abstract][Full Text] [Related]
2. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system.
Biegel JA; Janss AJ; Raffel C; Sutton L; Rorke LB; Harper JM; Phillips PC
Clin Cancer Res; 1997 Mar; 3(3):473-8. PubMed ID: 9815707
[TBL] [Abstract][Full Text] [Related]
4. Chromosome arm 17p deletion analysis reveals molecular genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system.
Burnett ME; White EC; Sih S; von Haken MS; Cogen PH
Cancer Genet Cytogenet; 1997 Aug; 97(1):25-31. PubMed ID: 9242214
[TBL] [Abstract][Full Text] [Related]
5. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis.
Cogen PH; Daneshvar L; Metzger AK; Duyk G; Edwards MS; Sheffield VC
Am J Hum Genet; 1992 Mar; 50(3):584-9. PubMed ID: 1347196
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic studies in medulloblastomas: evidence for tumor suppressor genes at the chromosomal regions 1q31-32 and 17p13.
Pietsch T; Koch A; Wiestler OD
Klin Padiatr; 1997; 209(4):150-5. PubMed ID: 9293446
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite analysis of loss of heterozygosity on chromosomes 9q, 11p and 17p in medulloblastomas.
Albrecht S; von Deimling A; Pietsch T; Giangaspero F; Brandner S; Kleihues P; Wiestler OD
Neuropathol Appl Neurobiol; 1994 Feb; 20(1):74-81. PubMed ID: 8208343
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
9. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
10. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma.
Emadian SM; McDonald JD; Gerken SC; Fults D
Clin Cancer Res; 1996 Sep; 2(9):1559-64. PubMed ID: 9816333
[TBL] [Abstract][Full Text] [Related]
11. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome.
Scheurlen WG; Schwabe GC; Joos S; Mollenhauer J; Sörensen N; Kühl J
J Clin Oncol; 1998 Jul; 16(7):2478-85. PubMed ID: 9667267
[TBL] [Abstract][Full Text] [Related]
13. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
Lang FF; Miller DC; Koslow M; Newcomb EW
J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular stratification of disease risk in medulloblastoma.
Gilbertson R; Wickramasinghe C; Hernan R; Balaji V; Hunt D; Jones-Wallace D; Crolla J; Perry R; Lunec J; Pearson A; Ellison D
Br J Cancer; 2001 Sep; 85(5):705-12. PubMed ID: 11531256
[TBL] [Abstract][Full Text] [Related]
15. Alterations of the TP53 gene in human gliomas.
Rasheed BK; McLendon RE; Herndon JE; Friedman HS; Friedman AH; Bigner DD; Bigner SH
Cancer Res; 1994 Mar; 54(5):1324-30. PubMed ID: 8118823
[TBL] [Abstract][Full Text] [Related]
16. Gene aberrations in childhood brain tumors.
Kucerová H; Stejskalová E; Vícha A; Tichý M; Chánová M; Sumerauer D; Koutechký J; Eckschlager T
Folia Biol (Praha); 2000; 46(5):187-90. PubMed ID: 11055797
[TBL] [Abstract][Full Text] [Related]
17. Correlation of gamma-catenin expression with good prognosis in medulloblastomas.
Misaki K; Marukawa K; Hayashi Y; Fukusato T; Minamoto T; Hasegawa M; Yamashita J; Fujisawa H
J Neurosurg; 2005 Mar; 102(2 Suppl):197-206. PubMed ID: 16156230
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor genes and medulloblastoma.
Cogen PH; McDonald JD
J Neurooncol; 1996 Jul; 29(1):103-12. PubMed ID: 8817421
[TBL] [Abstract][Full Text] [Related]
19. Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature.
Gilhuis HJ; Anderl KL; Boerman RH; Jeuken JM; James CD; Raffel C; Scheithauer BW; Jenkins RB
Clin Neurol Neurosurg; 2000 Dec; 102(4):203-209. PubMed ID: 11154805
[TBL] [Abstract][Full Text] [Related]
20. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma.
Adesina AM; Nalbantoglu J; Cavenee WK
Cancer Res; 1994 Nov; 54(21):5649-51. PubMed ID: 7923211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
